Brussels/Salamanca, January 9, 2017. The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies. Other organisations such as Myeloma Patients Europe (MPE), Lynphoma Coalition, MSD Alliance or CLL Advocate will be involved in this project as well in order to provide the patient perspective. Continue reading
ESMO.- A brain-boosting protein plays an important role in how well people respond to chemotherapy. This is what reveals a study presented at the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore. According to this research, cancer patients suffering depression have decreased amounts of brain-derived neurotrophic factor (BDNF) in their blood. Low levels make people less responsive to cancer drugs and less tolerant of their side-effects. Continue reading
Based on the findings of the European Atlas of Access to Myeloma Treatment, Myeloma Patients Europe’s Atlas Coaching Programme is an opportunity for MPE members to identify priorities and build successful advocacy strategies to improve access to myeloma treatments in every country in Europe. Continue reading
At the ESMO 2016 Congress held in Copenhagen between 7th-11th October, Dr Katja Weissel, from the Haematology and Oncology Department of Medicine at University Hospital Tuebingen (Germany), presented the results of the CASTOR study, a phase III randomised controlled study of daratumumab, bortezomib and dexamethasone (DVd) compared with bortezomib and dexamethasone (Vd) in patients with relapsed or refractory myeloma. Continue reading
MPE, in collaboration with other patient organisations, is conducting a project to analyse legal agreements of pharmaceutical companies with patient advocates. The project will make suggestions for simpler, more understandable agreements that would sufficiently reflect and protect the interests of both parties.
Ixazomib (Ninlaro®) has received a positive recommendation from the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency (EMA) for its use in relapsed myeloma patients. The decision follows an initial negative CHMP recommendation that was appealed by the pharmaceutical company, Takeda. Continue reading
Myeloma Patients Europe will hold an online webinar to provide an updated about the current myeloma diagnosis guidelines as well as a review of the current diagnosis techniques.
The talk will be given by Dr Guy Pratt, Honorary Consultant Haematologist at the Heart of England NHS Foundation Trust and Senior Lecturer in Haematology in the Institute of Immunology and Immunotherapy, University of Birmingham. Continue reading
Myeloma Patients Europe (MPE), in close collaboration with Myeloma UK, and along with almost 30 member and non-member associations across Europe, has submitted a letter to the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency (EMA) to encourage them to reconsider the negative recommendation for ixazomib, and provide information to the appeal of their decision on ixazomib. Continue reading
It is with great sadness that we share with you that our friend, colleague and Board member serving as secretary Mrs Christa Kolbe- Geipert passed away last Saturday, 23rd July 2016. Continue reading
Myeloma Patients Europe will hold an online webinar to review the most relevant myeloma updates presented at the annual meeting of the European Hematology Association that took place in Copenhagen in June 2016.
The talk will be given by Dr María Victoria Mateos, PhD. Director of the Myeloma Unit University Hospital of Salamanca-IBSAL Salamanca, Spain Continue reading